Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881189 | 1.00 | KMT2A (0.57) | KMT2AF10IGF1RMAPK14HTR4 | |
| SCHEMBL13181455 | 1.00 | KMT2A (0.57) | KMT2AF10IGF1RMAPK14HTR4 | |
| SCHEMBL13881274 | 0.92 | F10 (0.60) | KMT2AF10IGF1RHTR4 | |
| SCHEMBL13575481 | 0.90 | F10 (0.52) | KMT2AF10IGF1RHTR4CYP2D6 | |
| SCHEMBL12893788 | 0.88 | HTR4 (0.48) | KMT2AF10IGF1RHTR4CYP2D6 | |
| SCHEMBL12894062 | 0.88 | HTR4 (0.48) | KMT2AF10IGF1RHTR4CYP2D6 | |
| SCHEMBL1559039 | 0.86 | KMT2A (0.54) | KMT2AF10HTR4NPC1RAB9A | |
| SCHEMBL12389339 | 0.86 | F10 (0.58) | KMT2AF10HTR4CYP2D6CYP2C9 | |
| SCHEMBL12893438 | 0.85 | HTR4 (0.52) | KMT2AF10HTR4 | |
| SCHEMBL12893778 | 0.85 | HTR4 (0.52) | KMT2AF10HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138341-B2 | Intermediate compounds useful for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138341-B2 | Intermediate compounds useful for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138373-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138373-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | KMT2A 4420/4885F10 546/4885IGF1R 3097/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | KMT2A 4420/4885F10 546/4885IGF1R 3097/4885 |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | KMT2A 4420/4885F10 546/4885IGF1R 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.